A. Recruitment Developmental funds to support the recruitment of new investigators to the IUSCC will be critical in the next funding cycle to accomplish our strategic plan of the Center. During the current funding cycle, developmental funds were used to support the growth of research programs through targeted faculty recruitments. Investigators were recruited to all four IUSCC programs (Cancer Control, Hematopoiesis, Microenvironment and Immunology, Breast Cancer, and Experimental and Developmental Therapeutics) to accomplish the strategic objectives of the Center which had been identified as needing to increase our Gl, breast, epidemiology, lung cancer, and hematopoiesis faculty as well as cancer control members. Eighteen faculty members were successfully recruited with primary appointments in eight departments. Of these, ten now hold peer reviewed federal cancer research grants. All recruitment objectives discussed in the previous CCSG application were addressed (behavioral science and basic science focused on Gl and ovarian cancers). Future recruiting efforts in the upcoming grant cycle will be targeted toward expanding our Breast Cancer, Cancer Control and EOT Programs as well as the developing programs Molecular and Environmental Carcinogenesis and Tumor Microenvironment, outlined in the IUSCC Strategic Plan. CCSG funds are often a critical component of the packages that we use to recruit top candidates and provide the Cancer Center Director with real input into the recruitment of top cancer investigators into the institution. B. Pilot Projects: Developmental funds are also pivotally important for support of pilot research projects. Until September 2006, the IUSCC allocated pilot project funds by internal review of applications responding to specific RFA's. These RFA's could target a specific cancer type or research program. Some required collaboration with members of the Purdue Cancer Center and were jointly funded by both Centers. Review criteria included scientific relevance, collaboration and potential for future peer-reviewed funding. The IUSCC supported nineteen such projects, which are shown in Table 1 later in this section. Traditional use of funds for pilot funding of IUSCC projects changed dramatically when in September 2006, IUSCC Senior Leaders began a new and innovative approach for the allocation of pilot research funds.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Indiana University-Purdue University at Indianapolis
United States
Zip Code
Cohee, Andrea A; Adams, Rebecca N; Johns, Shelley A et al. (2017) Long-term fear of recurrence in young breast cancer survivors and partners. Psychooncology 26:22-28
Wang, Haiyan; Cai, Shanbao; Bailey, Barbara J et al. (2017) Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist. J Neurosurg 126:446-459
Caballero, Sergio; Kent, David L; Sengupta, Nilanjana et al. (2017) Bone Marrow-Derived Cell Recruitment to the Neurosensory Retina and Retinal Pigment Epithelial Cell Layer Following Subthreshold Retinal Phototherapy. Invest Ophthalmol Vis Sci 58:5164-5176
Salazar, Tatiana E; Richardson, Matthew R; Beli, Eleni et al. (2017) Electroacupuncture Promotes Central Nervous System-Dependent Release of Mesenchymal Stem Cells. Stem Cells 35:1303-1315
Kedage, Vivekananda; Strittmatter, Brady G; Dausinas, Paige B et al. (2017) Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation. J Biol Chem 292:17225-17235
Munnamalai, Vidhya; Sienknecht, Ulrike J; Duncan, R Keith et al. (2017) Wnt9a Can Influence Cell Fates and Neural Connectivity across the Radial Axis of the Developing Cochlea. J Neurosci 37:8975-8988
Hernandez-Perez, Marimar; Chopra, Gaurav; Fine, Jonathan et al. (2017) Inhibition of 12/15-Lipoxygenase Protects Against ?-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes. Diabetes 66:2875-2887
Hahn, Noah M; Bivalacqua, Trinity J; Ross, Ashley E et al. (2017) A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. Clin Cancer Res 23:3003-3011
Mohamad, Safa F; Xu, Linlin; Ghosh, Joydeep et al. (2017) Osteomacs interact with megakaryocytes and osteoblasts to regulate murine hematopoietic stem cell function. Blood Adv 1:2520-2528
Shah, Fenil; Goossens, Emery; Atallah, Nadia M et al. (2017) APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma - characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing. Mol Oncol 11:1711-1732

Showing the most recent 10 out of 236 publications